Xtx Topco LTD C4 Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.81 Billion
Q1 2025

A detailed history of Xtx Topco LTD transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 40,100 shares of CCCC stock, worth $50,526. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,100

Holding current value

$50,526

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$1.6 - $4.09 $64,160 - $164,009	40,100 New	40,100 $64,000
Q3 2024 Nov 14, 2024	BUY	$4.43 - $7.38 $376,332 - $626,938	84,951 New	84,951 $484,000
Q4 2023 Feb 13, 2024	SELL	$1.18 - $6.03 $88,310 - $451,279	-74,839 Reduced 77.92%	21,203 $119,000
Q3 2023 Nov 13, 2023	SELL	$1.81 - $3.89 $190,033 - $408,414	-104,991 Reduced 52.23%	96,042 $178,000
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $459,783 - $630,321	167,194 Added 494.09%	201,033 $552,000
Q1 2023 May 12, 2023	BUY	$3.1 - $9.02 $61,023 - $177,558	19,685 Added 139.08%	33,839 $106,000
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $8,699 - $16,435	1,605 Added 12.79%	14,154 $83,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $100,768 - $160,250	12,549 New	12,549 $110,000

Others Institutions Holding CCCC

# of Institutions

118

Shares Held

63.1M

Call Options Held

18.8K

Put Options Held

Lynx1 Capital Management LP San Juan, PR

7.1M
Shares

$8.94 Million
4.2% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

6.98M
Shares

$8.79 Million
0.92% of portfolio
Orbimed Advisors LLC San Diego, CA

6.83M
Shares

$8.61 Million
0.34% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

6.72M
Shares

$8.47 Million
0.06% of portfolio
Black Rock Inc. New York, NY

4.55M
Shares

$5.73 Million
0.0% of portfolio

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $61.6M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account